Health economics of prevention of coronary heart disease and vascular events: a cost-effectiveness analysis based on the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Jönsson
B
B
Stockholm School of Economics, Box 6501, S-113 83 Stockholm, Sweden. Bengt.Jonsson@hhs.se
Buxton
M
M
Hertzman
P
P
Kahan
T
T
Poulter
N
N
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis / Q000191:economics; D004232:Diuretics / Q000627:therapeutic use; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000191:economics*; D006973:Hypertension / Q000188:drug therapy / Q000191:economics*; D008875:Middle Aged; D012044:Regression Analysis; D015203:Reproducibility of Results
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics